Università Cattolica del Sacro Cuore, Roma, Italia
Luca Boldrini obtained his Medical Degree and completed his residency program in Radiotherapy at the Università Cattolica del Sacro Cuore of Rome, Italy.
He currently works as Radiation Oncologist at the Fondazione Policlinico Universitario “A. Gemelli” IRCCS - Università Cattolica del Sacro Cuore of Rome, where he is involved in the MRI guided radiotherapy research program.
His primary research interests include MRI guided radiotherapy, radiomics, imaging applications in the frame of personalised medicine and innovative technologies implementation in cancer care.
He is author of numerous scientific publication, books, and e-publications.
He is clinical coordinator of the radiomics research program of the Knowledge Based Oncology Lab (KBO Lab) of Rome, Italy.
He is currently a Ph.D. student in Oncological Sciences focusing on “Radiation Oncology, imaging and technological innovation” at the Università Cattolica del Sacro Cuore of Rome, Italy and member of several national and
international scientific associations.
Radiomics applications rectal cancer: the MRIdian perspective
The seminar will describe the potentialities of low T MRI guided hybrid Radiotherapy from a radiomics perspective. The talk will be focused on radiomics based prediction models for complete clinical response in rectal cancer patients undergoing neoadjuvant chemoradiotherapy.
EVEN MORE SEMINARS
Professor Anthony Howell The University of Manchester / The Christie NHS Foundation Trust
Improving risk estimation of breast cancer
Dr Catherine Coyle Christie Hospital NHS Foundation Trust
Prostate Cancer- the non surgical oncologists view
Dr Khurum Khan University College London Hospitals
Translational research in GI Oncology- how to make progress?
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations
Dr Qamar Ghafoor University Hospital Birmingham
Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.